Prognostic value of the Stanniocalcin-2/PAPP-A/IGFBP-4 axis in ST-segment elevation myocardial infarction

• Published in: Cardiovascular diabetology 2018-04, Vol.17 (1), p.63-63, Article 63
• Main Authors: Cediel, Germán, Rueda, Ferran, Oxvig, Claus, Oliveras, Teresa, Labata, Carlos, de Diego, Oriol, Ferrer, Marc, Aranda-Nevado, M Cruz, Serra-Gregori, Judith, Núñez, Julio, García, Cosme, Bayes-Genis, Antoni
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Biomarkers - blood; Cause of Death; Female; Glycoproteins - blood; Heart Failure - metabolism; Heart Failure - physiopathology; Heart Failure - therapy; Humans; IGFBP-4; Insulin-Like Growth Factor Binding Protein 4 - blood; Intercellular Signaling Peptides and Proteins - blood; Male; Middle Aged; Original Investigation; PAPP-A; Patient Readmission; Percutaneous Coronary Intervention; Predictive Value of Tests; Pregnancy-Associated Plasma Protein-A - analysis; Prognosis; Prospective Studies; Risk Factors; ST Elevation Myocardial Infarction - blood; ST Elevation Myocardial Infarction - mortality; ST Elevation Myocardial Infarction - physiopathology; ST Elevation Myocardial Infarction - surgery; Stanniocalcin-2; STEMI; Time Factors; Treatment Outcome; Ventricular Function, Left
• ISSN: 1475-2840; 1475-2840
• DOI: 10.1186/s12933-018-0710-3

The aim of the present study was to evaluate the prognostic value of the Stanniocalcin-2/PAPP-A/IGFBP-4 axis in patients with ST-segment elevation myocardial infarction (STEMI). Observational cohort study performed in 1085 consecutive STEMI patients treated with early reperfusion between February 2011 and August 2014. Stanniocalcin-2, PAPP-A, and IGFBP-4 were measured using state-of-the art immunoassays. The primary outcome was the composite endpoint of all-cause mortality and readmission due to heart failure (HF). Median follow-up was 3.3 years (IQR 1.0-3.7), during which 176 patients (16.2%) presented a composite endpoint. Multivariable cox regression analysis revealed that Stanniocalcin-2 (HR 2.06; 95% CI 1.13-3.75; p = 0.018), IGFBP-4 (HR 1.73; 95% CI 1.14-2.64; p = 0.010), Killip-Kimball class III-IV (HR 1.40; 95% CI 1.13-1.74; p = 0.002), NT-ProBNP (HR 1.21; 95% CI 1.07-1.37; p = 0.002), age (HR 1.06; 95% CI 1.04-1.08; p